Olmesartan Medoxomil/Hydrochloorthiazide Accord (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil, the active ingredient in Olmesartan Medoxomil/Hydrochloorthiazide Accord, is an angiotensin II receptor blocker presented as a combination tablet for oral use. It treats hypertension, often together with hydrochlorothiazide, and is prescribed for adults who need reliable blood‑pressure control.

GNH USA supplies Olmesartan Medoxomil/Hydrochloorthiazide Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance.

Olmesartan medoxomil/hydrochlorothiazide is used in the management of hypertension, a condition characterized by elevated arterial pressure.

- Essential hypertension: provides sustained blood‑pressure reduction when monotherapy is insufficient. - Secondary hypertension: assists in controlling pressure that originates from another underlying disorder. - Hypertension with fluid retention: combines an ARB with a thiazide diuretic to lower pressure and reduce excess fluid.

Adverse reactions may occur with any antihypertensive therapy.

Common Side Effects: - Dizziness or light‑headedness. - Headache. - Increased urinary frequency. - Mild electrolyte disturbances such as low potassium. - Fatigue. - Transient rise in serum creatinine.

Serious or Rare Side Effects: - Severe hypotension. - Hyperkalemia. - Acute renal failure. - Angioedema or severe allergic reaction. - Pancreatitis. - Life‑threatening electrolyte imbalances.

Before initiating therapy, clinicians should consider several safety aspects.

- Blood pressure monitoring: verify baseline and follow‑up readings after starting treatment. - Renal function: assess serum creatinine and eGFR prior to use and periodically thereafter. - Electrolyte balance: monitor potassium and sodium levels, especially when combined with other diuretics. - Pregnancy: avoid unless the potential benefit justifies the risk to the fetus. - Drug interactions: review all concomitant medicines for possible additive effects. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Olmesartan/HCTZ may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - Aliskiren in diabetic patients: increased risk of renal impairment. - NSAIDs: may blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely): - ACE inhibitors or other ARBs: additive blood‑pressure lowering. - Lithium: potential increase in lithium concentrations. - Other thiazide diuretics: may exacerbate electrolyte disturbances.